The pharmaceutical landscape for diabetes is changing, and transdermal GLP-1 delivery systems represent a potential advance. Unlike subcutaneous injections, this method offers a simpler way to administer GLP-1 drugs. These patches gradually release the drug through the skin offering a stable dose